
Oncocyte Corp (IMDX) Stock Forecast & Price Target
Oncocyte Corp (IMDX) Analyst Ratings
Bulls say
Insight Molecular Diagnostics Inc is positioned for substantial revenue growth, propelled by its advanced diagnostic tests targeting organ transplant monitoring and cancer. The company is exploring an addressable market expansion of approximately 10-20% as it seeks reimbursement for new testing indications related to immunosuppression and rejection monitoring, currently assessed in clinical trials. Furthermore, potential catalysts for financial performance include favorable clinical data presentations, changes in NCCN guidelines, and an acceleration in revenue growth exceeding projections.
Bears say
Insight Molecular Diagnostics Inc. is experiencing a decline in gross margin, which fell to 53.5% in the recent quarter from 67.6% in the previous year, although it exceeded estimates. The company's projected earnings per share have been revised downward to ($1.11) for 2025, reflecting concerns over cash burn and the potential impact of delayed insurer coverage and reimbursement. Additionally, significant risks such as slower physician adoption of new diagnostic tests and the anticipated lack of revenue until mid-2026, pending regulatory clearance for GraftAssureDx, contribute to the negative outlook for the stock.
This aggregate rating is based on analysts' research of Oncocyte Corp and is not a guaranteed prediction by Public.com or investment advice.
Oncocyte Corp (IMDX) Analyst Forecast & Price Prediction
Start investing in Oncocyte Corp (IMDX)
Order type
Buy in
Order amount
Est. shares
0 shares